C12N 2710/24022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/24022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 72 US grants and 53 published applications in this corpus.
Search patents in C12N- Granted patents
- 72
- Published applications
- 53
- Assignees
- 42
- Inventors
- 121
- Latest grant
- 17 Jun 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 2 | 0 |
| 1994 | 3 | 0 |
| 1995 | 5 | 0 |
| 1996 | 3 | 0 |
| 1997 | 2 | 0 |
| 1998 | 12 | 0 |
| 1999 | 7 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 0 |
| 2002 | 3 | 3 |
| 2003 | 2 | 7 |
| 2004 | 5 | 5 |
| 2005 | 2 | 1 |
| 2006 | 3 | 3 |
| 2007 | 0 | 2 |
| 2008 | 4 | 5 |
| 2009 | 2 | 2 |
| 2010 | 2 | 1 |
| 2011 | 0 | 3 |
| 2012 | 2 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 3 |
| 2016 | 0 | 2 |
| 2017 | 1 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 1 | 1 |
| 2021 | 1 | 5 |
| 2022 | 0 | 0 |
| 2023 | 1 | 2 |
| 2024 | 2 | 4 |
| 2025 | 2 | 2 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Oncolytic virus platform to treat cancers with myxoma virus17 Jun 2025US 12,331,079 B2Arizona Board of Regents on behalf of Arizona State University
- Recombinant adeno-associated viruses encoding serpin peptides and uses thereof15 Apr 2025US 12,274,757 B2University of Florida Research Foundation, Inc.
- Integral membrane protein display on poxvirus extracellular enveloped virions7 May 2024US 11,976,383 B2Vaccinex, Inc.
- Poxvirus host range protein K3 as a positive selection marker for generation of recombinant poxviruses, a therapeutic target for poxvirus infection and a therapeutic agent for PKR related diseases19 Mar 2024US 11,931,361 B2Her Majesty the Queen in right of Canada, as represented by the Minister of Health
- Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic27 Jun 2023US 11,685,767 B2University of Florida Research Foundation, Inc.
- Compositions and Methods for Enhancement of mRNA Vaccine Performance and Vaccination against Mpox18 Jun 2026US 2026/0166138 A1Yale University
- Enhancing oncolytic virotherapy with a combination of nuclear export inhibitor and myxoma virus activating cell death pathways25 Dec 2025US 2025/0387443 A1Arizona Board of Regents on behalf of Arizona State University
- Cancer therapies comprising a nuclear export inhibitor and an oncolytic virus7 Aug 2025US 2025/0249056 A1Arizona Board of Regents on behalf of Arizona State University
- Amino acids, nucleotides and vectors expressing the same and uses thereof in preventing sarbecovirus infection8 Aug 2024US 2024/0261389 A1National University of Singapore
- Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines25 Jul 2024US 2024/0245765 A1Poximmunomics LLC
Most cited
By later US patents
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Genetically engineered vaccine strain89US 5,364,773 AVirogenetics Corporation · 1994
- Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen89US 6,265,189 B1Virogenetics Corporation · 2001
- Modified recombinant vaccinia virus and expression vectors thereof65US 5,762,938 AVirogenetics Corporation · 1998